It's been 8 months in November since we were told:
"the U.S. FDA supports an accelerated approval pathway for rexlemestrocel-L, Mesoblast’s allogeneic mesenchymal precursor cell (MPC) product, in patients with end-stage ischemic heart failure with reduced ejection fraction (HFrEF) and a left ventricular assist device (LVAD)"
..... and still no meeting (that we know of) ? Get on with it ... lol
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$2.37 |
Change
-0.065(2.67%) |
Mkt cap ! $3.014B | |||
| Open | High | Low | Value | Volume |
| $2.40 | $2.42 | $2.34 | $6.539M | 2.757M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 18 | 25955 | $2.36 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.37 | 244847 | 42 |
View Market Depth
| Last trade - 15.17pm 07/08/2025 (20 minute delay) ? |
| MSB (ASX) Chart |